Pneumocystis jirovecii pneumonia in a patient receiving chemotherapy for advanced prostatic cancer: a case report

J Int Med Res. 2022 Jun;50(6):3000605221105358. doi: 10.1177/03000605221105358.

Abstract

Pneumocystis jirovecii pneumonia (PJP) in advanced prostatic cancer patients not receiving high-dose glucocorticoids has been reported rarely. A 73-year-old man underwent chemotherapy with cisplatin and docetaxel for advanced prostatic cancer. After nine cycles of chemotherapy, he developed a high fever, dry cough, shortness of breath, and severe fatigue, with rapid-onset hypoxic respiratory failure. Investigations demonstrated bilateral ground-glass opacities with positive bronchoalveolar lavage fluid (BALF) for Pneumocystis jirovecii by next-generation sequencings (NGS). The patient recovered well with treatment with trimethoprim-sulfamethoxazole, caspofungin, and corticosteroids. This case report describes a case of PJP in a patient with a solid tumor who did not receive high-dose glucocorticoids and emphasizes the importance of early diagnosis and treatment.

Keywords: Pneumocystis jirovecii; advanced prostatic cancer; bronchoalveolar lavage fluid; chemotherapy; ground-glass opacity; next-generation sequencing; respiratory failure; trimethoprim-sulfamethoxazole.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Glucocorticoids / therapeutic use
  • Humans
  • Male
  • Pneumocystis carinii*
  • Pneumonia, Pneumocystis* / diagnosis
  • Pneumonia, Pneumocystis* / drug therapy
  • Prostatic Neoplasms* / complications
  • Prostatic Neoplasms* / drug therapy
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Glucocorticoids
  • Trimethoprim, Sulfamethoxazole Drug Combination